Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - AzurRx BioPharma, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): September 27,
2017
AZURRX BIOPHARMA, INC.
|
|
|
Delaware
|
001-37853
|
46-4993860
|
(State
or Other Jurisdiction of
Incorporation
or Organization)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
No.)
|
|
|
|
760 Parkside Avenue
Downstate Biotechnology Incubator,
Suite 304
Brooklyn, New York
|
|
11226
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s telephone number, including area code:
(646) 699-7855
(Name,
address, including zip code, and telephone number, including area
code, of agent for service of process)
NOT
APPLICABLE
(Former
Name or Former Address, if Changes Since Last Report)
Check
the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions):
[
] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01
Other Events
On
September 27, 2017, the Company issued a press release announcing
positive MS1819-SD Phase II Data in Exocrine Pancreatic
Insufficiency (EPI). A copy of the press release is attached to
this Current Report on Form 8-K as Exhibit
99.1.
Item
9.01
Financial
Statements and Exhibits
(d) Exhibits.
Exhibit No.
|
|
Description
|
|
Press
Release dated September 27, 2017
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
AzurRx BioPharma, Inc.
|
Date:
September 27,
2017
By:
|
/s/
Johan M. Spoor
|
Name: Johan M. Spoor
|
|
Title: Chief Executive Officer
|
Exhibit Index